InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,412.92
(
1.28%
)
US TECH 100
18,393.60
(
1.87%
)
Dow Jones
39,674.22
(
0.81%
)
Brent Oil
80.46
(
-1.41%
)
Bitcoin
59,926.81
(
0.96%
)
Post# of 252867
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 136181

Tuesday, 05/01/2012 4:35:05 PM

Tuesday, May 01, 2012 4:35:05 PM

Post# of 252867
1Q12 US Tysabri sales were $201M, +18% YoY; half of the 18% increase was attributable to volume and half was attributable to price increases:

http://pharma411.visibli.com/share/ftNWk7
http://seekingalpha.com/article/547121-biogen-idec-s-ceo-discusses-q1-2012-results-earnings-call-transcript

Relative to 4Q11, US Tysabri sales increased 2.5%.

p.s. BIIB deserves credit for disclosing the change in unit volume as well as dollar sales; more biotech companies ought to do that.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up